Summary
Thermo Fisher Scientific Inc. reported solid revenue growth in the second quarter and first half of 2025, driven by strong performance in its Life Sciences Solutions and Laboratory Products and Biopharma Services segments. While overall revenue increased by 3% and 2% respectively for the periods, the company's profitability metrics showed some mixed signals. Operating income saw marginal increases, but operating income margins experienced slight declines, attributed to unfavorable business mix, strategic investments, and tariff impacts. The company also announced a significant pending acquisition of Solventum Corporation's Purification and Filtration business for approximately $4.0 billion, expected to close by year-end 2025, which will further bolster the Life Sciences Solutions segment. Despite a slight decrease in free cash flow compared to the prior year, driven by increased debt issuance and share repurchases, Thermo Fisher maintains a strong liquidity position and expects to meet its cash requirements. The company continues to execute its growth strategy focused on innovation, customer partnerships, and its commercial engine, while managing costs through productivity improvements and restructuring efforts. Investors should monitor the integration of recent and pending acquisitions and the ongoing impact of global economic conditions on customer spending, particularly in the Analytical Instruments segment.
Financial Highlights
54 data points| Revenue | $10.86B |
| R&D Expenses | $352.00M |
| SG&A Expenses | $2.14B |
| Operating Expenses | $9.02B |
| Operating Income | $1.83B |
| Net Income | $1.62B |
| EPS (Basic) | $4.28 |
| EPS (Diluted) | $4.28 |
| Shares Outstanding (Basic) | 378.00M |
| Shares Outstanding (Diluted) | 378.00M |
Key Highlights
- 1Total revenues increased by 3% to $10.86 billion for the three months ended June 28, 2025, and by 2% to $21.22 billion for the six months ended June 28, 2025.
- 2Operating income saw a modest increase of 1% to $1.83 billion for the quarter and 2% to $3.55 billion for the six months, though operating margin slightly decreased due to business mix and strategic investments.
- 3The company announced a pending acquisition of Solventum Corporation's Purification and Filtration business for approximately $4.0 billion, expected to close by the end of 2025.
- 4Free cash flow for the first six months of 2025 was $1.48 billion, a decrease from $2.58 billion in the prior year, reflecting higher debt issuance and share repurchases.
- 5The Life Sciences Solutions segment reported strong revenue growth of 6% for the quarter and 4% for the six months, driven by the bioproduction business and the Olink acquisition.
- 6The Analytical Instruments segment experienced revenue declines of 3% for the quarter and 1% for the six months, attributed to tariffs and reduced demand from academic and government customers.
- 7Thermo Fisher repurchased $2.00 billion of its common stock in the first six months of 2025 and has a new authorization to repurchase up to $4.00 billion.